Renova Therapeutics, Inc.
CARLSBAD, CA · CIK 0002036392 · Biotech · Private
AAV8 gene therapy vector encoding urocortin 2 (UCn2) for type-1 diabetes treatment
renovatherapeutics.com →- Grants
- $5.0M
- 6 awards
- Sector median: 1
- Raised
- $167K
- 1 Form D · Sep 2024
- 25 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 2
- 0 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Urocortin-2 Gene Transfer for CHF: a Paracrine Approach Using Intravenous AAV8 | $802,500 | |
| Federal grant | Department of Health and Human Services · Phase II · Urocortin Gene Transfer for CHF a Paracrine Approach Using Intravenous AAV | $1,605,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Urocortin-2 Gene Transfer for CHF: a Paracrine Approach Using Intravenous AAV8 | $802,500 | |
| Federal grant | Department of Health and Human Services · Phase II · Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction | $241,698 | |
| Federal grant | Department of Health and Human Services · Phase II · Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction | $805,659 | |
| Federal grant | Department of Health and Human Services · Phase II · Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction | $792,556 | |
| Private capital raised | Form D · SEC | $166,500 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2638 | Ayala Pharmaceuticals, Inc. | — | $45M |
| 2639 | YOUNG THERAPEUTICS, LLC | — | — |
| 2640 | Avant Sciences, Inc. | — | $175K |
| 2641 | Renova Therapeutics, Inc. | — | $167K |
| 2642 | BIONANOTECH LLC | — | — |
| 2643 | GREFFEX, INC. | — | $155K |
| 2644 | RITROVA THERAPEUTICS INC. | — | $150K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Roy CosanDirector
- William DavidsonDirector
- Kirk HammondDirector
- Pierre LecocqDirector
- Vijay MahantDirector
- Shawn SwaneyExecutive Officer
- Michael TorresDirector
- Morgan XuDirector
Patents
- Method Of Protection For Cardiac Tissueapplication
- Methods Of Treating Heart Failureapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.